Saerens, M.; De Jaeghere, E.A.; Kanervo, H.; Vandemaele, N.; Denys, H.; Naert, E.
Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. Cancers 2021, 13, 4603.
https://doi.org/10.3390/cancers13184603
AMA Style
Saerens M, De Jaeghere EA, Kanervo H, Vandemaele N, Denys H, Naert E.
Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. Cancers. 2021; 13(18):4603.
https://doi.org/10.3390/cancers13184603
Chicago/Turabian Style
Saerens, Michael, Emiel A. De Jaeghere, Heini Kanervo, Nele Vandemaele, Hannelore Denys, and Eline Naert.
2021. "Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis" Cancers 13, no. 18: 4603.
https://doi.org/10.3390/cancers13184603
APA Style
Saerens, M., De Jaeghere, E. A., Kanervo, H., Vandemaele, N., Denys, H., & Naert, E.
(2021). Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. Cancers, 13(18), 4603.
https://doi.org/10.3390/cancers13184603